If the giant pharmaceutical companies of the world seem quite big enough to you already, well, that just means you probably aren’t a major investor in or CEO of one. But the major investors and CEOs do think bigger is better, and so to that end two of them are merging to create an even bigger drug behemoth and take it overseas. [More]
The folks at Allergan, the company behind the popular Lap-Band weight loss surgery, have 26 million reasons to cheer today. After all, that’s the number of potential new Lap-Band patients now that the FDA has lowered the minimum weight loss requirements for the procedure. [More]
Oh no! Brooke Shields used to have stringy, stick-figure eyelashes! I figured this out after watching Consumer Reports’ video dissection of a new commercial for Latisse, the glaucoma medication that has been rebranded as an expensive, temporary eyelash enhancer with side effects.
Who knew botulism could be so awesome? Botox is Allergan’s cash cow, earning the pharmaceutical company $1.3 billion last year alone. The funny thing about the toxin—originally developed as a biological weapon—is it works for a lot of “off-label” uses as well (like treating anal fissures and preventing hair loss), and Allergan says that non-cosmetic applications could be an even bigger market because health insurers will help pay for the treatments. Likely upcoming FDA-approved treatments: stroke-induced muscle spasms, chronic migraines, and enlarged prostates.